Reports Q4 revenue $108.185M, consensus $100.67M. Michael Weiss, the Company’s Chairman and Chief Executive Officer, stated, “2024 was a year of significant outperformance and growth for TG, highlighted by the strong adoption of BRIUMVI for adult patients with relapsing forms of multiple sclerosis, which surpassed our initial expectations. Additionally, we made meaningful progress in strengthening our BRIUMVI patent portfolio through 2042, launching new clinical trials, including for subcutaneous BRIUMVI, and advancing our pipeline. These accomplishments provide a solid foundation as we look toward continued success in 2025.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TGTX:
- Options Volatility and Implied Earnings Moves Today, March 03, 2025
- TGTX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- MaxCyte enters strategic platform license with TG Therapeutics
- TG Therapeutics Reports Strong Revenue and Future Goals
- TG Therapeutics sees Q4 BRIUMVI U.S. net product revenue $103.6M